CRISM Therapeutics Corporation (AIM:CRTX)

Market Cap	7.68M
Revenue (ttm)	25.00K
Net Income (ttm)	-607.00K
Shares Out	32.68M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,240
Average Volume	37,141
Open	22.10
Previous Close	23.50
Day's Range	22.00 - 23.65
52-Week Range	5.00 - 30.90
Beta	0.27
RSI	63.03
Earnings Date	Jun 19, 2025

About CRISM Therapeutics

CRISM Therapeutics Corporation focuses on drug delivery technology to improve the clinical performance of cancer drugs as treatments for solid tumors. Its lead product, ChemoSeed that can be implanted directly into a tumor or the resection margin following the removal of a tumor, ensuring effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. Its ChemoSeed used for treatment of gliomas, a brain tumor. The company was founded in 2016 and is based in Road Town, the British Virgin Islands.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 4
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: CRTX

Financial Performance

In 2024, CRISM Therapeutics's revenue was 25,000, a decrease of -44.44% compared to the previous year's 45,000. Losses were -607,000, 209.7% more than in 2023.